Findings of amplitude-integrated electroencephalogram recordings and serum vitamin B6 metabolites in perinatal lethal hypophosphatasia during enzyme replacement therapy

Tomonori Ishiguro, Yuichiro Sugiyama, Kazuto Ueda, Yukako Muramatsu, Hiroyuki Tsuda, Tomomi Kotani, Toshimi Michigami, Kanako Tachikawa, Tomoyuki Akiyama, Masahiro Hayakawa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Hypophosphatasia (HPP) is a rare disorder caused by low serum tissue non-specific alkaline phosphatase (ALP) activity due to hypomorphic mutations in the ALPL gene. HPP is characterized by defective bone mineralization. It frequently accompanies pyridoxine-responsive seizures. Because alkaline phosphatase change pyridoxal 5′ phosphate (PLP) into pyridoxal (PL), which can cross the blood brain barrier and regulates inhibitory neurotransmitter gamma-aminobutyric acid. The female patient was born at a gestational age of 37 weeks 2 days. She presented severe respiratory disorder due to extreme thoracic hypoplasia. With the extremely low serum ALP value (14 IU/L), she was clinically diagnosed as HPP. The diagnosis was confirmed with genetic testing. On day1, the subclinical seizures were detected by aEEG. Together with enzyme replacement therapy by asfotase alfa, pyridoxine hydrochloride was administered, then the seizures were rapidly controlled. While confirming that there was no seizure by aEEG monitoring, pyridoxine hydrochloride was gradually discontinued after 1 month. Before administration of pyridoxine hydrochloride, PL was extremely low (4.7 nM) and PLP was increased (1083 nM). After the withdrawal, PL was increased to 84.9 nM only by enzyme replacement. Monitoring with aEEG enabled early intervention for pyridoxine responsive seizures. Confirming increased serum PL concentration is a prudent step in determining when to reduce or discontinue pyridoxine hydrochloride during enzyme replacement therapy.

Original languageEnglish
Pages (from-to)721-725
Number of pages5
JournalBrain and Development
Volume41
Issue number8
DOIs
Publication statusPublished - Sep 1 2019

Fingerprint

Enzyme Replacement Therapy
Pyridoxine
Vitamin B 6
Pyridoxal
Electroencephalography
Hypophosphatasia
Seizures
Serum
Alkaline Phosphatase
Pyridoxal Phosphate
Physiologic Calcification
Partial Epilepsy
Genetic Testing
Blood-Brain Barrier
gamma-Aminobutyric Acid
Gestational Age
Neurotransmitter Agents
Perinatal Lethal Hypophosphatasia
Thorax
Mutation

Keywords

  • Alkaline phosphatase
  • Neonatal seizure
  • Pyridoxal
  • Pyridoxal 5′ phosphate
  • Pyridoxine dependent seizures
  • Subclinical seizure

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Developmental Neuroscience
  • Clinical Neurology

Cite this

Findings of amplitude-integrated electroencephalogram recordings and serum vitamin B6 metabolites in perinatal lethal hypophosphatasia during enzyme replacement therapy. / Ishiguro, Tomonori; Sugiyama, Yuichiro; Ueda, Kazuto; Muramatsu, Yukako; Tsuda, Hiroyuki; Kotani, Tomomi; Michigami, Toshimi; Tachikawa, Kanako; Akiyama, Tomoyuki; Hayakawa, Masahiro.

In: Brain and Development, Vol. 41, No. 8, 01.09.2019, p. 721-725.

Research output: Contribution to journalArticle

Ishiguro, Tomonori ; Sugiyama, Yuichiro ; Ueda, Kazuto ; Muramatsu, Yukako ; Tsuda, Hiroyuki ; Kotani, Tomomi ; Michigami, Toshimi ; Tachikawa, Kanako ; Akiyama, Tomoyuki ; Hayakawa, Masahiro. / Findings of amplitude-integrated electroencephalogram recordings and serum vitamin B6 metabolites in perinatal lethal hypophosphatasia during enzyme replacement therapy. In: Brain and Development. 2019 ; Vol. 41, No. 8. pp. 721-725.
@article{31b0d60fdebe4cd0acb8bd3e0b375290,
title = "Findings of amplitude-integrated electroencephalogram recordings and serum vitamin B6 metabolites in perinatal lethal hypophosphatasia during enzyme replacement therapy",
abstract = "Hypophosphatasia (HPP) is a rare disorder caused by low serum tissue non-specific alkaline phosphatase (ALP) activity due to hypomorphic mutations in the ALPL gene. HPP is characterized by defective bone mineralization. It frequently accompanies pyridoxine-responsive seizures. Because alkaline phosphatase change pyridoxal 5′ phosphate (PLP) into pyridoxal (PL), which can cross the blood brain barrier and regulates inhibitory neurotransmitter gamma-aminobutyric acid. The female patient was born at a gestational age of 37 weeks 2 days. She presented severe respiratory disorder due to extreme thoracic hypoplasia. With the extremely low serum ALP value (14 IU/L), she was clinically diagnosed as HPP. The diagnosis was confirmed with genetic testing. On day1, the subclinical seizures were detected by aEEG. Together with enzyme replacement therapy by asfotase alfa, pyridoxine hydrochloride was administered, then the seizures were rapidly controlled. While confirming that there was no seizure by aEEG monitoring, pyridoxine hydrochloride was gradually discontinued after 1 month. Before administration of pyridoxine hydrochloride, PL was extremely low (4.7 nM) and PLP was increased (1083 nM). After the withdrawal, PL was increased to 84.9 nM only by enzyme replacement. Monitoring with aEEG enabled early intervention for pyridoxine responsive seizures. Confirming increased serum PL concentration is a prudent step in determining when to reduce or discontinue pyridoxine hydrochloride during enzyme replacement therapy.",
keywords = "Alkaline phosphatase, Neonatal seizure, Pyridoxal, Pyridoxal 5′ phosphate, Pyridoxine dependent seizures, Subclinical seizure",
author = "Tomonori Ishiguro and Yuichiro Sugiyama and Kazuto Ueda and Yukako Muramatsu and Hiroyuki Tsuda and Tomomi Kotani and Toshimi Michigami and Kanako Tachikawa and Tomoyuki Akiyama and Masahiro Hayakawa",
year = "2019",
month = "9",
day = "1",
doi = "10.1016/j.braindev.2019.03.015",
language = "English",
volume = "41",
pages = "721--725",
journal = "Brain and Development",
issn = "0387-7604",
publisher = "Elsevier",
number = "8",

}

TY - JOUR

T1 - Findings of amplitude-integrated electroencephalogram recordings and serum vitamin B6 metabolites in perinatal lethal hypophosphatasia during enzyme replacement therapy

AU - Ishiguro, Tomonori

AU - Sugiyama, Yuichiro

AU - Ueda, Kazuto

AU - Muramatsu, Yukako

AU - Tsuda, Hiroyuki

AU - Kotani, Tomomi

AU - Michigami, Toshimi

AU - Tachikawa, Kanako

AU - Akiyama, Tomoyuki

AU - Hayakawa, Masahiro

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Hypophosphatasia (HPP) is a rare disorder caused by low serum tissue non-specific alkaline phosphatase (ALP) activity due to hypomorphic mutations in the ALPL gene. HPP is characterized by defective bone mineralization. It frequently accompanies pyridoxine-responsive seizures. Because alkaline phosphatase change pyridoxal 5′ phosphate (PLP) into pyridoxal (PL), which can cross the blood brain barrier and regulates inhibitory neurotransmitter gamma-aminobutyric acid. The female patient was born at a gestational age of 37 weeks 2 days. She presented severe respiratory disorder due to extreme thoracic hypoplasia. With the extremely low serum ALP value (14 IU/L), she was clinically diagnosed as HPP. The diagnosis was confirmed with genetic testing. On day1, the subclinical seizures were detected by aEEG. Together with enzyme replacement therapy by asfotase alfa, pyridoxine hydrochloride was administered, then the seizures were rapidly controlled. While confirming that there was no seizure by aEEG monitoring, pyridoxine hydrochloride was gradually discontinued after 1 month. Before administration of pyridoxine hydrochloride, PL was extremely low (4.7 nM) and PLP was increased (1083 nM). After the withdrawal, PL was increased to 84.9 nM only by enzyme replacement. Monitoring with aEEG enabled early intervention for pyridoxine responsive seizures. Confirming increased serum PL concentration is a prudent step in determining when to reduce or discontinue pyridoxine hydrochloride during enzyme replacement therapy.

AB - Hypophosphatasia (HPP) is a rare disorder caused by low serum tissue non-specific alkaline phosphatase (ALP) activity due to hypomorphic mutations in the ALPL gene. HPP is characterized by defective bone mineralization. It frequently accompanies pyridoxine-responsive seizures. Because alkaline phosphatase change pyridoxal 5′ phosphate (PLP) into pyridoxal (PL), which can cross the blood brain barrier and regulates inhibitory neurotransmitter gamma-aminobutyric acid. The female patient was born at a gestational age of 37 weeks 2 days. She presented severe respiratory disorder due to extreme thoracic hypoplasia. With the extremely low serum ALP value (14 IU/L), she was clinically diagnosed as HPP. The diagnosis was confirmed with genetic testing. On day1, the subclinical seizures were detected by aEEG. Together with enzyme replacement therapy by asfotase alfa, pyridoxine hydrochloride was administered, then the seizures were rapidly controlled. While confirming that there was no seizure by aEEG monitoring, pyridoxine hydrochloride was gradually discontinued after 1 month. Before administration of pyridoxine hydrochloride, PL was extremely low (4.7 nM) and PLP was increased (1083 nM). After the withdrawal, PL was increased to 84.9 nM only by enzyme replacement. Monitoring with aEEG enabled early intervention for pyridoxine responsive seizures. Confirming increased serum PL concentration is a prudent step in determining when to reduce or discontinue pyridoxine hydrochloride during enzyme replacement therapy.

KW - Alkaline phosphatase

KW - Neonatal seizure

KW - Pyridoxal

KW - Pyridoxal 5′ phosphate

KW - Pyridoxine dependent seizures

KW - Subclinical seizure

UR - http://www.scopus.com/inward/record.url?scp=85070777005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070777005&partnerID=8YFLogxK

U2 - 10.1016/j.braindev.2019.03.015

DO - 10.1016/j.braindev.2019.03.015

M3 - Article

C2 - 31000369

AN - SCOPUS:85070777005

VL - 41

SP - 721

EP - 725

JO - Brain and Development

JF - Brain and Development

SN - 0387-7604

IS - 8

ER -